Two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal oues in these patients.Are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics.Sustained released (SR) is a fixed-dosebination of trandolapril and a sustained release formulation of verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure.Efficacy of trandolapril/verapamil SR has been evaluated extensively in large trials.The INVEST trial, a verapamil SR-based treatment strategy that included trandolapril in most patients was effective in reducing the primary oue in hypertensive patients with coronary artery disease.Onset of diabetes was also significantly lower in the verapamil SR/trandolapril treatment group inparison with those on the atenolol/hydroclorothiazide treatment group.BErgamo NEphrologic DIabetesplications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, trandolapril plus verapamil or trandolapril alone delayed the onset of microalbuminuria independent of their blood pressurereducing effect.Trandolapril/verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.Read more Fda panel recommends against avastin approval
Get more Senator writes of cancer (AP)
